Change in lean mass during pharmacologically induced weight reduction
What proportion of the mass lost during treatment with an incretin receptor agonist is lean rather than fat mass, and does it differ from that lost through caloric restriction?
§1Abstract
§1.1Review question
What proportion of the mass lost during treatment with an incretin receptor agonist is lean rather than fat mass, and does it differ from that lost through caloric restriction?
§1.2PICO frame
Table 1. The registered PICO frame. Any change made after protocol registration is recorded in the amendment log at §5 and is identified there as post hoc.
| Element | As registered |
|---|---|
| Population | Adults undergoing weight reduction with an incretin receptor agonist and with a body-composition assessment. |
| Intervention | Incretin receptor agonist with dual-energy X-ray absorptiometry or magnetic resonance body-composition assessment. |
| Comparator | Placebo, or caloric restriction achieving a comparable weight change. |
| Outcomes | Absolute and proportional change in lean mass, appendicular lean mass index, and any functional measure. |
§1.3Method in brief
A structured map of the available evidence for a question where the Institute judges that a quantitative synthesis is not yet supportable. A scoping review states what would have to exist before an intervention review could be attempted. The protocol was registered with the Institute's secretariat before the search was executed. The search was run on 12 April 2024 across 8 sources and is reproduced in full at §2. Screening, extraction and certainty assessment were performed independently by two members of the secretariat with disagreement resolved by a third.
§1.4Conclusion
Low certainty evidence from body-composition sub-studies embedded in weight-loss trials indicates that the proportion of mass lost that is lean tissue in incretin-induced weight reduction ranges from approximately 25 percent to 40 percent, with substantial variation between individuals and measurement modalities. This proportion is broadly comparable with that observed during caloric-restriction-induced weight loss in small observational studies, though the comparison crosses different measurement methods. The Institute publishes this as a scoping review rather than an intervention review for the specific reason that no sub-study was powered for the lean-mass endpoint, all contributing measurements come from selected sub-populations within parent trials, and no functional outcome has been measured. The clinical significance of lean-mass loss at this magnitude—whether it represents a loss of functional capacity, metabolic consequence, or a measurement artefact of hydration change—is unresolved, and no trial has stratified its functional outcomes by baseline lean-mass change.
The conclusion rests on 17 contributing studies, listed with their extracted data at §3 and summarised outcome by outcome at §4.
§1.5Limitations
§1.6Consultation
This review was released for public comment before ratification. Draft scoping review: change in lean mass during pharmacologically induced weight reduction received 7 submissions. Amendments arising are recorded in the amendment log and are traceable to a numbered submission.